共查询到20条相似文献,搜索用时 0 毫秒
1.
T. J. Speakman 《CMAJ》1963,89(13):652-656
Surgical destruction of a portion of the ventrolateral nucleus of the thalamus is currently the procedure of choice for the treatment of incapacitating tremor and rigidity of parkinsonism. Seventy-three patients were treated by 105 thalamotomies at the University of Alberta Hospital and assessed one to four years later for improvement of function in everyday activities. Fifty-six patients were improved, 12 were unchanged, and five had died. Only two of the deaths were related to the operation. Paresis was permanent in only one patient. Twenty-five patients had bilateral operations and 22 of these showed improvement of function. Contraindications to operation include serious cardiovascular disease, mental deterioration, and those parkinsonian patients whose disability is chiefly due to akinesia, oculogyric crisis, dysphasia or dysarthria. 相似文献
2.
目的:观察左旋多巴/卡比多巴联合恩他卡朋(levodopa/carbidopa combined with entacapone,LC+E)治疗帕金森病(Parkinson's disease,PD)的临床效果。方法:选择我院2013年1月~2014年6月收治的112例PD患者,随机分为两组。其中对照组52例采用左旋多巴/卡比多巴(LC)治疗,观察组60例采用左旋多巴/卡比多巴联合恩他卡朋(LC+E)治疗。观察并比较两组治疗前后帕金森病评分量表(Unified Parkinson's Disease Rating Scale,UPDRS)的评分变化情况。结果:与治疗前比较,治疗后两组UPDRS-II日常生活能力评分,UPDRS-III运动能力评分显著下降,而UPDRS-VI SCHWABENGLAND日常活动能力评分显著上升,差异有统计学意义(P0.05);观察组各项变化情况比对照组明显,差异有统计学意义(P0.05)。两组UPDRS-I精神、行为、情绪和Hoehn与Yahr分级均无显著改善,差异无统计学意义(P0.05)。结论:左旋多巴/卡比多巴联合恩他卡朋可明显缓解PD症状,疗效优于左旋多巴/卡比多巴治疗,且安全性高,值得临床推广。 相似文献
3.
Leo J. Treciokas Robert D. Ansel Charles H. Markham 《The Western journal of medicine》1971,114(5):7-14
One hundred patients with Parkinson''s disease were treated with levodopa for more than a year at UCLA Medical Center. They were examined at given intervals and their improvement was graded. The optimum therapeutic dose was attained by balancing side effects against relief of symptoms and ranged from 1.5 grams to 8.0 grams per day (average 4.3 grams). There is no doubt that levodopa is the most effective treatment now available for Parkinson''s disease. At the end of the first year, 60 percent of the patients improved 50 percent or better, and 10 percent were considered symptom-free. All major symptoms of this disease, including rigidity, akinesia and tremor, improved in variable degree.There were no serious abnormalities in the routine clinical laboratory tests. The comon side effects included nausea, vomiting and choreoathetoid dyskinesias. The side effects were not life threatening, but occasionally were major therapeutic challenges.Maximal benefits with minimal side effects were achieved only by careful adjustments of the levodopa dosage as the months went by. This needed careful management by the physician and cooperation by the patient. Anticholinergic medications or amantadine hydrochloride, sometimes both, usually supplemented the effect of the levodopa. 相似文献
4.
Ramon B. Jenkins Sander H. Mendelson Sofjan Lamid Harold L. Klawans 《BMJ (Clinical research ed.)》1972,3(5825):512-514
Forty patients with Parkinsonism and heart disease were studied before and during the administration of levodopa. Patients with increasing angina, myocardial infarction within the previous year, pre-existing severe postural hypotension, or transient cerebral ischaemia were excluded. Thirty-eight patients showed no adverse effects; angina improved in one patient but later worsened; one patient died of myocardial infarction after a severe gastrointestinal haemorrhage. Therapy with levodopa appears to pose little increased hazard to patients with most forms of heart disease. Inpatient monitoring is recommended at the beginning of therapy, and antiarrhythmic agents should be used when required. 相似文献
5.
6.
《Endocrine practice》2014,20(6):e112-e115
ObjectiveThe diagnosis of pheochromocytoma in patients receiving levodopa is challenging because the standard diagnostic biochemical tests may be confounded by dopaminergic therapy. We aim to showcase our experience with the diagnosis of pheochromocytoma in a patient with a known case of Parkinson’s disease who was receiving levodopa.MethodsWe present the case of an elderly male who was diagnosed as having pheochromocytoma while receiving dopaminergic therapy for Parkinson’s disease.ResultsA 75-year-old man presented with vague abdominal symptoms. Computed tomography revealed a 3.5 × 3.2 cm right adrenal mass with a well-defined margin. As revealed by magnetic resonance imaging, the mass was hypointense on T1-weighted and hyperintense on T2-weighted images. Biochemical tests revealed elevated levels of urinary dopamine, which was considered to be caused by levodopa therapy. However, concurrent elevation in urinary adrenaline and his metanephrine and vanillylmandelic acid levels suggested an underlying case of pheochromocytoma. An 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy scan performed under levodopa therapy showed positive tracer uptake in the right adrenal gland. Histopathology of the adrenalectomy specimen confirmed the diagnosis of pheochromocytoma.ConclusionOur experience with the present case indicates that although the standard diagnostic biochemical tests for pheochromocytoma may be confounded by dopaminergic therapy, 123I-MIBG scintigraphy has diagnostic value for confirming pheochromocytoma even in patients receiving dopaminergic therapy. (Endocr Pract. 2014;20:e112-e115) 相似文献
7.
《BMJ (Clinical research ed.)》1981,282(6262):417-418
8.
目的:探讨左旋多巴治疗帕金森病(PD)时测定血同型半胱氨酸水平的临床意义。方法:收集我院内科2012年3月到2014年3月住院和门诊的PD患者50例(病例组),选取健康体检者50例作为对照组,比较两组同型半胱氨酸、叶酸以及维生素B12差异以及同型半胱氨酸与叶酸、维生素B12和左旋多巴剂量和PD患者评分(UPDRS评分)相关性。结果:病例组血浆同型半胱氨酸水平显著高于对照组、差异具有的统计学意义(P0.05),叶酸以及维生素B12低于对照组,两组之间的差异具有统计学意义(P0.05);按照血浆同型半胱氨酸剂量将病例组分为两个亚组,高剂量组(≥14μmol/L)和低剂量组(14μmol/L),两亚组叶酸、维生素B12、左旋多巴剂量和UPDRS评分之间差异均无统计学意义(P0.05);相关性分析发现,同型半胱氨酸与叶酸、维生素B12以及UPDRS评分呈负相关(r=-0.545,-0.337,-0.233,P=0.001,0.009,0.013),与左旋多巴剂量呈正相关(r=0.518,P=0.001)。结论:左旋多巴治疗PD可使血同型半胱氨酸水平升高并降低叶酸、维生素B12的含量,临床上应加强叶酸、维生素B12等营养支持治疗。 相似文献
9.
帕金森病和阿尔茨海默氏病是世界范围内最普遍的神经退行性疾病.常规药物和手术治疗只能缓解症状,不能推迟或者终止疾病进程.近年来分子生物学与医学研究进展促进了对帕金森病和阿尔茨海默氏病发病机制的深入了解,为其基因治疗策略提供了理论和实验依据.综述了目前帕金森病、阿尔茨海默氏病的基因治疗研究进展.基因治疗作为帕金森病和阿尔茨海默氏病的一种全新治疗手段,无疑对于了解帕金森病和阿尔茨海默氏病的病因及其全面治疗具有重要意义. 相似文献
10.
The authors report their experience, over a 26-month period, in the management of 60 parkinsonian patients with the combination of levodopa and an inhibitor of peripheral dopa-decarboxylase, Ro 4-4602. This approach to Parkinson''s disease is useful, safe, and at least as effective as levodopa alone. To date there have been no recognizable toxic effects attributable to Ro 4-4602. This agent appears to prolong the duration of action of levodopa, smoothing out its therapeutic effects. The percentage of patients obtaining a very good and excellent response is slightly increased. There is a possible diminution in the late-occurring bradykinetic and hypotonic freezing episodes. Nausea and cardiac arrhythmias are lessened, as are the incidence and severity of hypotension. Abnormal involuntary movements remain the limiting adverse side effect. 相似文献
11.
干细胞为治疗帕金森病提供了新的希望.目前用于研究的干细胞主要有神经干细胞、胚胎干细胞、诱导多功能干细胞、间充质干细胞等.本文回顾了上述细胞在移植治疗帕金森病研究中的进展,并介绍了近期出现的将体细胞直接重编程为神经细胞或神经干细胞的新技术. 相似文献
12.
目的:探究左旋多巴联合综合疗法治疗屈光不正性弱视患儿的临床效果。方法:选取2013年4月至2016年3月在我院接受治疗的屈光不正性弱视青少年103例(180眼),随机分为对照组52例(90眼)和观察组51例(90眼)。对照组患儿给予常规的综合治疗,观察组在对照组之上给予左旋多巴治疗。治疗6个月后,观察比较两组患儿的治疗有效率、图形视觉诱发电位(P-VEP)、视觉对比敏感度和视功能等以及不良反应的发生情况。结果:观察组的视力治疗有效率为90.00%,显著高于对照组(68.89%),差异具有统计学意义(P0.05)。治疗6个月后,两组的振幅出现明显的升高,且观察组显著高于对照组(P0.05);两组的潜伏期发生明显降低,且观察组的显著低于对照组(P0.05)。观察组患儿的100%、25%、10%及5%空间频率视觉对比敏感度均显著低于对照组(P0.05)。观察组患儿的矫正辐辏范围、矫正分开范围显著高于对照组,矫正近立体锐度显著低于对照组(P0.05)。治疗期间,两组不良反应发生情况比较差异无统计学意义(P0.05)。结论:左旋多巴联合综合疗法可有效改善屈光不正患儿的视觉中枢神经元功能,明显提高视力水平及视觉敏感度。 相似文献
13.
胚胎干细胞起源于植入前胚胎的内细胞团(inner cell mass,ICM),能够在体外进行增殖并能分化成三个胚层的所有细胞类型.如果能有效地将胚胎干细胞(embryonic stem cell,ES细胞)诱导分化为特定的细胞类型,ES细胞将成为细胞替代治疗中供体细胞的一个理想来源,从而可以应用于帕金森病(Parkinson's disease,PD)、糖尿病、心脓死等的退行性病变疾病的治疗.近年来,将ES细胞来源的多巴胺能神经元用于PD治疗的研究越来越广泛.现对这些研究中有关基因表达调控、实验研究进展、临床应用以及所遇到的问题作一综述.虽然这些研究还没能最终大面积应用于临床.但为PD的治疗提供了一个广阔的应用前景. 相似文献
14.
Hasriza Hashim Shahrul Azmin Hamizah Razlan Nafisah Wan Yahya Hui Jan Tan M. Rizal Abdul Manaf Norlinah Mohamed Ibrahim 《PloS one》2014,9(11)
Background
Previous studies have demonstrated a higher prevalence of Helicobacter pylori (H. pylori) infection in patients with Parkinson''s disease (PD) compared to controls. H. pylori infection affects levodopa absorption and its eradication significantly improves clinical response to levodopa. Here, we studied the prevalence of H. pylori infection and its eradication effects among our PD patients.Methods
A prospective study involving idiopathic PD patients on levodopa therapy. 13C-urea breath test (UBT) was used to detect H. pylori. UBT-positive patients were given standard eradication therapy and followed up at 6 and 12 weeks in an open label single arm design. Repeat UBT was performed at 12 weeks. The UPDRS, PD NMQ, PD NMSS and PDQ-39 were administered at baseline and post-eradication (6 and 12 weeks). Levodopa ‘onset’ time and ON-duration were recorded.Results
Of 82 patients recruited, 27 (32.9%) had positive UBT. H. pylori-positive patients had significantly poorer total UPDRS (p = 0.005) and PDQ39 (p<0.0001) scores compared to H. pylori-negative patients. At 12 weeks post-eradication, the mean levodopa onset time shortened by 14 minutes (p = 0.011). The mean ON duration time increased by 56 minutes at week 6 (p = 0.041) and 38 minutes at week 12 (p = 0.035). The total UPDRS scores (p<0.0001), scores for parts II (p = 0.001), III (p<0.0001) and IV (p = 0.009) were significantly better. The total PDQ-39 scores (p = 0.001) and subdomains mobility (p = 0.002), ADL (p = 0.001), emotional well being (p = 0.026) and stigma (p = 0.034) significantly improved. The PD NMSQ did not show significant improvement.Conclusions
H. pylori eradication improved levodopa onset time, ON duration, motor severity and quality of life parameters. Screening and eradication of H. pylori is inexpensive and should be recommended in PD patients, particularly those with erratic response to levodopa.Trial Registration
ClinicalTrials.gov NCT02112812相似文献15.
目的:探讨文拉法辛联合认知行为疗法治疗帕金森病(PD)抑郁、认知功能障碍的临床疗效和安全性。方法:选择我院收治的60例PD合并抑郁、认知功能障碍患者并将其随机分为三组,分别为对照组(单用文拉法辛治疗),联合奥氮平组(文拉法辛联合奥氮平),联合认知行为疗法组(文拉法辛联合认知行为疗法),每组20例,于治疗前及治疗后4、8周末采用汉密尔顿抑郁量表(HAMD)进行抑郁程度评定,简易精神状态评价量表(MMSE)和事件相关电位(event-related potentials,ERPs)P300进行认知功能评定。结果:治疗4、8周时,三组的HAMD评分均较治疗前有不同程度下降,P300潜伏期较治疗前有不同程度缩短,P300波幅、MMSE评分有不同程度升高(P0.05),联合奥氮平组和联合认知行为疗法组HAMD评分较对照组明显下降,P300潜伏期较对照组明显缩短,P300波幅、MMSE评分明显升高(P0.05),联合认知行为疗法组HAMD评分较联合奥氮平组明显下降,P300潜伏期明显缩短,P300波幅、MMSE评分明显升高(P0.05)。三组均无特殊不良反应。结论:文拉法辛联合认知行为疗法治疗PD抑郁、认知功能障碍疗效确切,能显著改善患者抑郁症状,提高患者的认知功能,疗效较单用文拉法辛或文拉法辛联合奥氮平治疗更好,且安全性高。 相似文献
16.
André Barbeau 《CMAJ》1969,101(13):59-68
The last 10 years have seen great activity in the investigation of cerebral catecholamines, particular attention having been paid to dopamine. The low dopamine content in the basal ganglia and in the urine of patients with Parkinson''s disease led to the logical use of the precursor DOPA in the treatment of this disorder. Between 1961 and 1966, both the oral and the intravenous routes were utilized and some effects were noted upon akinesia and rigidity. The doses then used were low and the results remained somewhat controversial. When higher oral levels of L-dopa were introduced, the beneficial action of L-dopa upon parkinsonian symptoms and signs was proved beyond doubt, but there came to light a number of troublesome side effects, the worst of which were hypotension and a variety of abnormal involuntary movements. Recently, new approaches to the therapy have been tried and the sum total of these observations is to challenge our peace of mind regarding a seemingly logical chain of events. We are convinced that such second thoughts will eventually result in better and safer methods of treating this too frequent and disabling neurological disorder. 相似文献
17.
18.
目的:观察西药抗氧化剂依达拉奉联合中药葛根素在帕金森病治疗中的效果及安全评价。方法:选取2011年8月-2013年12月哈尔滨医科大学附属第四医院神经内科收治的帕金森病人80例,随机均分为实验组和对照组。实验组给予口服美多巴,同时静滴依达拉奉和葛根素,对照组仅予口服美多巴治疗,疗程2周,治疗前后比较UPDRS评分、不良反应,观察血清氧化酶学指标的变化。结果:治疗后,实验组的四项UPDRS评分改善均显著优于对照组,且实验组不良反应亦显著低于对照组;两组患者的血清氧化酶学指标检测与治疗前比有明显改善,差异均具有统计学意义(P0.05)。结论:在口服美多巴治疗基础上,联合应用依达拉奉和葛根素,对帕金森病的治疗显示出更好的效果,并有利于减轻药物的不良反应,可能跟调控抗氧化酶有关。 相似文献
19.
Disease model: Parkinson's disease 总被引:4,自引:0,他引:4
Parkinson's disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopaminergic neurons in the nigrostriatal pathway. The pathology of PD is typified by the presence of cytoplasmic inclusions (Lewy bodies) containing alpha-synuclein and ubiquitin. The pathogenesis of PD is not completely understood but environmental and genetic factors are thought to play important roles. To understand the pathophysiology of PD, and to develop novel therapies for improved symptomatic management, it is important to have relevant disease models. In this review, we summarize the available in vivo and in vitro models of PD and discuss their value. 相似文献
20.
目的研究观察蛇毒酶治疗帕金森氏病(PD)、帕金森综合征(PS)的临床效果,方法对82例PD和PS患者进行随机分组,A组应用精制蝮蛇抗栓酶,B组应用东菱克栓酶,C组应用力源精纯溶栓酶;对每例病人进行治疗前后Webster记分和记录多巴制剂的递减/递增量,同时检测血液流变学和血凝学5项指标,并给予统计比较,结果A组病例不论是临床症状的改善,还是多巴制剂的用量递减、血液流变学和血凝学指标变化均优于B、C 相似文献